PrEP Injectable Has Higher Adherence and Lower Exposure to HIV - 25/09/2026 - Equilibrio E Saúde

Globo

Lean Right

Factuality

Ownership

Cabotegravir is an injectable medicine for HIV prevention Disclosure A Brazilian study published on Thursday (24) in the scientific journal The Lancet HIV showed that people who used cabotegravir injection as a pre-exposure prophylaxis (PrEP) against HIV had 90.8% of the days of follow-up covered by prevention. Among participants who used oral PrEP, currently available in the Unified Health System (SUS), this index was 35.5%. 我Like g1 in Google …

Poder360

Factuality

Ownership

Cabotegravir received a favourable preliminary recommendation from Conitec; Ministry of Health plans to expand the range of prevention. Read on Power360.

Folha de S.Paulo

Factuality

Ownership

Cabotegravir, PrEP (pre-exposure prophylaxis) injection that should be made available in the SUS (Single Health System), offers greater coverage and lower incidence of HIV, according to a study by Fiocruz (Oswaldo Cruz Foundation) published on Thursday (24) in Lancet magazine. Read more (09/25/2026)

CNN Brasil

Factuality

Ownership

According to the research, the application of the injection drug resulted in a significant reduction in the incidence of HIV and an increase in the coverage of PrEP (Pre-Exposure Prophylaxis); alternative is evaluated to be included in SUS